Investing.com -- Bernstein analysts told investors in a note Tuesday that Eli Lilly (NYSE:LLY) is gaining ground in the GLP-1 market, edging closer to market share parity with Novo Nordisk (NYSE:NVO).
The firm’s latest GLP-1 tracker is said to show Lilly’s market share rising to 49.1% for the four-week period ending February 21, up from 48.8% the previous week.
Bernstein explained that “LLY taking even more market share” has been driven primarily by continued momentum in Zepbound, which now holds 17.8% of the market, up from 17.3% last week.
Meanwhile, they note that Mounjaro is steadily growing, with a four-week year-over-year growth rate of 61%, up from 55% last week.
Overall, the GLP-1 category is said to remain on a strong growth trajectory. Bernstein notes that total weekly prescriptions across semaglutide (Novo Nordisk’s Ozempic and Wegovy) and tirzepatide (Lilly’s Mounjaro and Zepbound) hit 1.49 million for the week ending February 21.
While this reportedly represents a 3% weekly decline, the firm attributes the dip to normal fluctuations rather than a meaningful slowdown, as the four-week sequential growth rate remained steady at 7%, with year-over-year growth increasing to 63% from 60% in the prior report.
Novo Nordisk continues to grow, but at a slower pace than Lilly, according to Bernstein.
“Interestingly both LLY and NOVO are demonstrating yoy growth that aligns with volume guidance +30% of supply growth for NOVO, 1.6x supply growth for LLY,” wrote Bernstein.
The firm’s analysts highlight that Novo’s total GLP-1 prescriptions rose 38% year-over-year, up slightly from 36% last week, but have yet to benefit from an increase in available starter doses in the U.S.
Bernstein maintained an Outperform rating on Eli Lilly with a $1,100 price target, citing strong momentum in GLP-1 adoption and continued market share expansion.
Related Articles
GLP1 Tracker: Lilly continues to outgrow Novo- analyst
CK Hutchison to sell Panama ports' stake to group including BlackRock amid Trump pressure
South Korea and US to form working group on Alaska LNG project, tariffs
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。